VanEck Associates
NVAX icon

VanEck Associates’s Novavax NVAX Stock Holding History

VanEck Associates’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-109,388
Closed -$5.63M – 1413
2022
Q2 		$5.63M Sell
109,388
-19,618
-15% -$1.02M 0.01% 439
2022
Q1 		$9.5M Buy
129,006
+10,980
+9% +$979K 0.02% 370
2021
Q4 		$16.9M Buy
118,026
+1,101
+0.9% +$189K 0.04% 280
2021
Q3 		$24.2M Sell
116,925
-19,149
-14% -$4.22M 0.06% 229
2021
Q2 		$28.9M Sell
136,074
-31,524
-19% -$5.78M 0.07% 216
2021
Q1 		$30.4M Buy
167,598
+57,294
+52% +$11.4M 0.08% 181
2020
Q4 		$12.3M Buy
110,304
+34,889
+46% +$3.71M 0.04% 277
2020
Q3 		$8.17M Buy
+75,415
New +$9.19M 0.03% 288

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

VanEck Associates's NVAX Position: Q3 2022 in Review

VanEck Associates sold out of Novavax (NVAX) in Q3 2022, closing a stake of 109,388 shares — an estimated $5.63M sold.

VanEck Associates first reported a position in NVAX in Q3 2020 and held it in 8 quarters. The position peaked at $30.4M in Q1 2021. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

  • VanEck Associates reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
  • VanEck Associates sold 109,388 Novavax shares in Q3 2022, an estimated $5.63M.
  • VanEck Associates first reported a position in Novavax in Q3 2020 and held it in 8 quarters.
  • VanEck Associates's Novavax position peaked at $30.4M in Q1 2021.
  • 253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on VanEck Associates's 13F filing for Q3 2022, filed 27 Oct 2022.